The immune response in patients with cutaneous leishmaniasis and the influence of zinc supplementation

An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis

Leishmaniasis is a Neglected Tropical Diseases caused by protozoan parasites of the genus Leishmania. It is a major health problem in many tropical and subtropical regions of the world and can produce three different clinical manifestations, among which cutaneous leishmaniasis has a higher incidence in the world than the other clinical forms. There are no recognized and reliable means of chemoprophylaxis or vaccination against infections with different forms of leishmaniasis. In addition, chemotherapy, unfortunately, remains, in many respects, unsatisfactory. Therefore, there is a continuing and urgent need for new therapies against leishmaniasis that are safe and effective in inducing a long-term cure. This review summarizes the latest advances in currently available treatments and improvements in the development of drug administration. In addition, an analysis of the in vivo assays was performed and the challenges facing promising strategies to treat CL are discussed. The treatment of leishmaniasis will most likely evolve into an approach that uses multiple therapies simultaneously to reduce the possibility of developing drug resistance. There is a continuous effort to discover new drugs to improve the treatment of leishmaniasis, but this is mainly at the level of individual researchers. Undoubtedly, more funding is needed in this area, as well as greater participation of the pharmaceutical industry to focus efforts on the development of chemotherapeutic agents and vaccines for this and other neglected tropical diseases.

Vitamins A and D and Zinc Affect the Leshmanicidal Activity of Canine Spleen Leukocytes

Simple Summary

Canine leishmaniasis (CanL) is a zoonosis caused by the protozoan Leishmania infantum, with dogs being considered the main domestic reservoirs of the parasite and potential transmitters to humans through the phlebotomine vector. CanL is a chronic infectious disease that characteristically occurs in underdeveloped and developing countries, with a broad spectrum of clinical and immunopathological manifestations. Despite the efforts in the fight against the disease, many endemic sites of CanL persist, preceding human infection and representing a serious public health problem. The therapeutic arsenal for the treatment of leishmaniasis is limited by toxicity, high costs, and inefficacy, in some cases. Treatment failure implies the permanence of dogs as reservoirs of the parasite, with further aggravation of the public health problem, indicating that new therapies should be evaluated in order to increase the treatment efficacy. Recent studies have shown that nutrients can regulate the immune response in many clinical conditions, but no study has been conducted using spleen leukocytes in CanL. In this paper, we demonstrate for the first time that nutrients added to cultures of spleen leukocytes from dogs infected with CanL can modulate the immune response and parasite load compared to healthy dogs.

Abstract

Canine leishmaniasis (CanL) is a chronic disease caused by Leishmania infantum, and the limitations of the current treatments have encouraged new alternatives, such as the use of immunomodulatory nutrients. The objective of this study was to determine the serum levels of vitamin A (retinol), vitamin D (25(OH)VD₃), and zinc (Zn) in dogs with CanL and the effect of in vitro supplementation with the respective active forms ATRA, 1,25(OH)₂VD₃, and SZn on spleen leukocyte cultures. Serum retinol, 25(OH)VD₃, and Zn were determined by HPLC, ELISA, and ICP-MS, respectively. Spleen leukocyte cultures were used for the detection of NO and ROS by flow cytometry; the IFN-γ, TNF-α, and IL-10 levels were determined by ELISA; and the parasite load was determined by microscopy. We detected low serum levels of retinol and Zn and high levels of 25(OH)VD₃ in the CanL group. The in vitro supplementation of CanL spleen leukocytes with ATRA, 1,25(OH)₂VD₃, and SZn, in addition to a soluble leishmania antigen (SLA) treatment, increased the NO and ROS levels, while the treatments with only ATRA and SZn increased the TNF-a levels. Increased IL-10 and IFN-g levels were observed with the addition of SLA to the medium, although the addition of the three nutrients led to a reduction of the IL-10 levels, and the addition of 1,25(OH)₂VD₃ and SZn led to a reduction of IFN-g. A supplementation with 1,25(OH)₂VD₃ and SZn reduced the parasite load but only in the absence of SLA. We suggest that the nutrients we tested are involved in the leishmanicidal mechanism, showing a potential for investigation in future studies.